Teva UK has launched generic co-beneldopa (Levodopa/Benserazide) capsules in a variety of strengths.
“We’re delighted to be launching co-beneldopa capsules,” said Kim Innes, Commercial Director, Teva UK Limited. “This product fits well with our range and strengthens our position as the UK’s leading generics supplier. It comes hot on the heels of diamorphine hydrochloride (HCL) powder for injection, oxcarbazepine tablets and topiramate tablets, which were added to our product portfolio during the last quarter.”
Co-beneldopa is a dopaminergic drug indicated for treatment of symptoms of Parkinson’s disease. It is a generic version of Madopar (co-beneldopa), which is manufactured by Roche.
“At the moment over 50% of scripts are written by brand. If all scripts were written and dispensed generically the potential saving to the NHS would be over £341,000 annually,” added Kim Innes.
Teva is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid- and liquid-dose injectable and respiratory medicines to healthcare professionals.